PMV Pharmaceuticals (NASDAQ:PMVP – Get Rating) and NovaBay Pharmaceuticals (NYSE:NBY – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.
This is a breakdown of recent ratings and recommmendations for PMV Pharmaceuticals and NovaBay Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PMV Pharmaceuticals presently has a consensus target price of $44.25, indicating a potential upside of 207.93%. NovaBay Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 1,450.39%. Given NovaBay Pharmaceuticals’ higher probable upside, analysts plainly believe NovaBay Pharmaceuticals is more favorable than PMV Pharmaceuticals.
Volatility and Risk
Institutional and Insider Ownership
3.2% of NovaBay Pharmaceuticals shares are owned by institutional investors. 9.9% of PMV Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of NovaBay Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares PMV Pharmaceuticals and NovaBay Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|PMV Pharmaceuticals||N/A||N/A||-$57.85 million||($1.44)||-9.98|
|NovaBay Pharmaceuticals||$8.42 million||1.61||-$5.82 million||($0.11)||-2.35|
NovaBay Pharmaceuticals has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares PMV Pharmaceuticals and NovaBay Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NovaBay Pharmaceuticals beats PMV Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.